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Emerging Justifications for Placebic Treatment
Tejas Pulisetty

I spent the summer of 2011 collecting data for my global health research in the urban and rural locales of eastern
Ghana. Besides learning how to say “Do you have any organic
chicken left?” in the native Twi dialects, and how not to dance
to the music of the pop star Amako, I learned of the depth of
an inveterate ethical dilemma.
During the daily eye health outreaches in the rural villages
where I volunteered, one of the Ghanaian ophthalmologists
would routinely prescribe tetracycline ointments for patients,
despite believing that the patients were perfectly healthy.
When we asked why, he responded, “They come here because
they feel that they need a checkup. When they go home with
something in their hands, they feel satisfied and happy that
they received a tangible treatment from the clinic.”
The reader may sense something amiss here, but at the moment, I didn’t think much of it. Perhaps it was merely a cultural difference that I was unaware of—or perhaps the doctor
was on to something.
It turns out that clinicians routinely prescribe unnecessary
medications much more frequently than was previously
known—and this occurs not only in Ghana, but also in developed countries.
For instance, in the United States, it is not entirely impossible
to imagine a scenario in which a patient walks into a clinic
and the doctor has a diagnosis that is so difficult to make that
the doctor ends up giving the patient a medication that they
know will not biochemically or physically address the patient’s
condition. This is confirmed statistically—an investigation of
3,848 patient visits over a one year period to an established
general practice revealed that in roughly half of all initial general practice patient-doctor consultations, a firm diagnosis
could not be made as a result of the patient presenting with
vague symptoms instead of a specific chief complaint.1 Why,
then, would the doctor choose to provide the patient with a
medication that is not biochemically or physically proven to
address the symptoms? Because such treatments have been
shown to work for many decades in a variety of scenarios.
A 1987 British study divided a collection of 200 patients, for
whom no clinical diagnoses could be made, into separate
groups. One group received honest feedback and was told
that the clinician did not know what caused their problems. A
second group received false feedback and was not only given a
specific diagnosis, but was also told that they would definitely
get better in the next several days. Interestingly, this second
group was more than 64% more likely to experience an improvement in symptoms than the other group.2 If this is the
case, why doesn’t every caregiver do this?
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In real clinical scenarios, placebic treatment is a controversial grappling between the bioethical principles of autonomy
and beneficence. Placebos are inert substances or treatments
that are prescribed for psychological rather than physiological
benefit. In order for placebos to work, the personal interactions between a caregiver and a patient must somehow convey
to the patient a suggestion of a positive outcome. If the suggestion is unintentional on the part of the caregiver, it is not
considered a form of deception.3 The suggestion may also be
honest and intentional yet incomplete. For instance, the physician may say to the patient, “I am prescribing a pill which
research suggests can be of benefit to you. In your circumstances, I have reason to believe that it will work with minimal
side effects.”4 This can be considered a mild form of deception
because the patient is intentionally led to believe that he or she
is getting a real physiological treatment instead of a placebo.
In this situation, the deception clearly prioritizes beneficence
and violates patient autonomy. Or does it?
It can be argued that the decision to give the patient an honest
and informed definition of the placebic treatment could potentially dissuade the patient from receiving the placebo, thus
leading the patient to choose to go untreated and effectively
eliminating the option to be treated. Ultimately, this would result in a paradoxical loss of autonomy from the patient’s perspective.4 Bennet Foddy, a senior research fellow at the Oxford Institute for Science and Ethics, notes that “whether the
patient takes the placebo or refuses it, the pharmacological
outcome is the same,” considering that a placebo is inert. Furthermore, Foddy states that “the only difference is that in one
case, the patient forms a self-benefiting false belief.”4 By this
logic, it would seem that prescribing a placebo results in a net
gain for the patient. Indeed, the theme here is that the patient’s
right to refuse a thoroughly-explained and unveiled placebic
treatment is overridden by the potential benefits a patient can
receive from a placebo and the drug’s inert nature.4
In further support of placebo use, Professor Foddy provocatively adds:
Doctors have a duty to do the best they can to relieve a
patient’s symptoms. If that means they prescribe a placebo,
or even conduct a séance…then there is a duty to do these
things. If a doctor can really suggest to a patient that a
chant will cure his headache, then it very likely will, and
she should ululate it at the top of her lungs…It is a type of
deception that patients ought to be thankful for, just as we
are thankful when we receive a mendacious compliment
from a friend.4
Overall the support for placebic treatments is argumentatively diverse, and the umbrella argument of proponents for
placebos is that physicians are obligated to do the best they
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can to relieve a patient’s symptoms.5 An interesting observation is that placebic treatments may, in certain cases, be one
of the best possible treatments. For example, placebos have
been shown to be unusually effective in psychiatric depression as well as irritable bowel syndrome (which may involve
a substantial psychiatric component).5 Proponents also point
out that placebic treatments are often significantly less costly
than treatments such as antibiotics or diagnostic tools such as
MRI, both of which are not always deemed necessary in initial
patient-physician encounters.
However, the opposition is just as robust on the other side.
Even though placebic treatments are currently less costly than
true pharmacological treatments or diagnostic tools, prescription drugs in general add to a national burden of drug
costs, and placebic drugs may further contribute to this burden in the future. In fact, it was recently shown that the more
expensive a placebo is, the stronger its therapeutic effect may
become.6 Furthermore, prescription drugs, via incorrect dosage or unintended use, have been shown statistically to kill
106,000 Americans per year, and prescribing excessive, costly, and physically unnecessary medications is an obviously
condemnable habit.7,8 Additionally, while emphasizing the
violation of basic principles of the doctor-patient relationship, those who oppose and question placebic treatments also
contend that such treatments indirectly lead to hazardous
results. These opponents further believe that placebic treatment should not be used in a real clinical setting but should be
strictly limited to laboratory clinical trials. After all, resorting
to clinically unsubstantiated treatments may delay a proper
diagnosis of a serious illness.7 Thus, there exists a solid body of
opposition to such behavior by doctors. In fact, the American
Medical Association delineated an ethical policy that prohibits the deceptive use of placebos in clinical practice, in which
physicians are barred from giving patients “a substance…that
the physician believes has no specific pharmacological effect
upon the condition being treated.”9 Additional data is needed
to better describe the relative amount of opposition and support of placebos by professionals.
One survey revealed that approximately “half of [all] internists
and rheumatologists” in the U.S. routinely prescribe placebic
treatments for patients with debilitating chronic conditions.10
In an Israeli hospital, a retrospective questionnaire revealed
that 37% of physicians prescribed placebos at least once per
month, and 94% of all placebo-prescribers believed they were
effective.11 A Danish survey estimated that 48% of Danish clinicians prescribed placebos more than ten times in a given
year, and that 46% believed that placebic treatments are ethically acceptable.12 A Canadian survey found that 80% of clinicians in one hospital admitted to using placebos at least once
in a given year.13 Finally, a New Zealand survey “indicated that
almost all [general practitioners] surveyed would deliberately
use a [placebic] treatment under some circumstances.”14
Regardless of the interpretations of modern data, the strength
of the support, or the force of the opposition, placebic treatment will remain an option that is very useful for some patients and less useful to others. Although this debate has

historically been level, the modern ethical arguments presented here, in combination with
the evidence of positive support by health professionals and students, seems to show substantial ethical rationale and professional support for the use of
placebos in clinical practice. Placebos are “the most commonly prescribed drug across cultures and throughout history,”
and as aforementioned, there is violation of neither patient
autonomy nor beneficence in the use of placebos.2 Although
one cannot assert with certainty that the Ghanaian ophthalmologist who prescribed tetracycline that summer should be
commended for his behavior, it is apparent that he has done
no harm and has not strayed from the societal nor professional guidelines of modern medicine.
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